SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/246552"
 

Search: onr:"swepub:oai:gup.ub.gu.se/246552" > Long-term valacyclo...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Long-term valacyclovir suppressive treatment after herpes simplex virus type 2 meningitis: a double-blind, randomized controlled trial.

Aurelius, E (author)
Karolinska Institutet
Franzen-Röhl, E (author)
Karolinska Institutet
Glimåker, M (author)
show more...
Akre, O (author)
Karolinska Institutet
Grillner, L (author)
Karolinska Institutet
Jorup-Rönström, C (author)
Studahl, Marie, 1957 (author)
Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine
show less...
 (creator_code:org_t)
2012-03-28
2012
English.
In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. - : Oxford University Press (OUP). - 1537-6591. ; 54:9, s. 1304-13
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Herpes simplex virus type 2 (HSV-2) is a common cause of acute and recurrent aseptic meningitis. Our aim was to determine the impact of antiviral suppression on recurrence of meningitis and to delineate the full spectrum of neurological complications.One hundred and one patients with acute primary or recurrent HSV-2 meningitis were assigned to placebo (n = 51) or 0.5 g of valacyclovir twice daily (n = 50) for 1 year after initial treatment with 1 g of valacyclovir 3 times daily for 1 week in a prospective, placebo-controlled, multicenter trial. The primary outcome was time until recurrence of meningitis. The patients were followed up for 2 years.The first year, no significant difference was found between the valacyclovir and placebo groups. The second year, without study drugs, the risk of recurrence of verified and probable HSV-2 meningitis was significantly higher among patients exposed to valacyclovir (hazard ratio, 3.29 [95% confidence interval, 10.06-10.21]). One-third of the patients experienced 1-4 meningitis episodes during the study period. A considerable morbidity rate, comprising symptoms from the central, peripheral, and autonomous nervous system, was found in both groups.Suppressive treatment with 0.5 g of valacyclovir twice daily was not shown to prohibit recurrent meningitis and cannot be recommended for this purpose after HSV meningitis in general. Protection against mucocutaneous lesions was observed, but the dosage was probably inappropriate for the prevention of HSV activation in the central nervous system. The higher frequency of meningitis, after cessation of active drug, could be interpreted as a rebound phenomenon.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

Keyword

Acyclovir
administration & dosage
analogs & derivatives
therapeutic use
Adult
Antiviral Agents
administration & dosage
therapeutic use
Double-Blind Method
Female
Follow-Up Studies
Herpes Simplex
drug therapy
prevention & control
virology
Herpesvirus 2
Human
drug effects
Humans
Male
Meningitis
Viral
drug therapy
prevention & control
virology
Prospective Studies
Secondary Prevention
Sweden
Treatment Outcome
Valine
administration & dosage
analogs & derivatives
therapeutic use

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view